Antitrombomoduline/THBD Antilichaampicoband® fluoro488 Vervoeging

The protein encoded by this intronless gene is an endothelial-specific type I membrane receptor that binds thrombin. This binding results in the activation of protein C, which degrades clotting factors Va and VIIIa and reduces the amount of thrombin generated. Mutations in this gene are a cause of thromboembolic disease, also known as inherited thrombophilia.

Wee1-like protein kinase; WEE1hu; Wee1A kinase; WEE1

THBD

7056

P07204

Human, Rat

No cross-reactivity with other proteins.

E.coli-derived human Thrombomodulin/THBD recombinant protein (Position: Q29-L575) .

Predominantly expressed in T-cells. Also detected in proliferating intestinal epithelial cells and in the basal epithelial cells of mammary gland epithelium.

Flow Cytometry

Cell Biology, Cell Cycle, Epigenetics and Nuclear Signaling, Kinases/Phosphatases

Immunogen affinity purified.

Liquid

Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.

1. Anastasiou, G., Gialeraki, A., Merkouri, E., Politou, M., Travlou, A. Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis. Blood Coagul. Fibrinolysis 23: 1-10, 2012. 2. Cole, J. W., Roberts, S. C., Gallagher, M., Giles, W. H., Mitchell, B. D., Steinberg, K. K., Wozniak, M. A., Macko, R. F., Reinhart, L. J., Kittner, S. J. Thrombomodulin ala455val polymorphism and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study. BMC Neurol. 4: 21-27, 2004. 3. Delvaeye, M., Noris, M., De Vriese, A., Esmon, C. T., Esmon, N. L., Ferrell, G., Del-Favero, J., Plaisance, S., Claes, B., Lambrechts, D., Zoja, C., Remuzzi, G., Conway, E. M. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. New Eng. J. Med. 361: 345-357, 2009.

At -20 ̊C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

60066 MW

6

WEE1 G2 checkpoint kinase

Nucleus.

Heparanase

Rabbit IgG

Each vial contains 50% glycerol, 0.9% NaCl, 0.2% Na2HPO4, 0.02% NaN3.